FDA Intervenes Against Cox-2 Pain Inhibitors, Wiping Out "Wonder Drugs" Myth

Strategic Insights -

The Food and Drug Administration's intervention against Pfizer's Bextra and Celebrex marks the end of the illusion that cox-2 pain inhibitors are safe and effective alternatives to conventional pain medications. The withdrawal of Bextra, following a request from the FDA, leaves only one cox-2 blockbuster on the US market, Celebrex, which must now carry the strongest warning possible in its labeling, cautioning users of the potential risk of heart attacks and strokes. The FDA's decision reflects a collapse in confidence in cox-2 drugs, triggered by the controversy surrounding their safety and the withdrawal of Merck's Vioxx in September. The labeling requirement for Celebrex will not only put it on equal footing with older, cheaper medications but may also raise the hurdle for the approval of other experimental cox-2 drugs.

Key Takeaways:

  • The FDA's intervention against Pfizer's Bextra and Celebrex signals the end of the cox-2 pain inhibitor class as a "wonder drug" option, highlighting concerns over their safety and effectiveness.
  • The withdrawal of Bextra and the warning labeling for Celebrex are a significant blow to the pharmaceutical industry, as they put cox-2 drugs on equal footing with older, cheaper medications.
  • The FDA's decision may raise the hurdle for the approval of other experimental cox-2 drugs, such as Merck's Arcoxia, Novartis's Prexige, and GlaxoSmithKline's compound.
  • The labeling requirement for Celebrex will advise users of the potential increased risk of cardiovascular events and the well-described, serious, and potentially life-threatening gastrointestinal bleeding associated with these drugs.
  • Pfizer sees the FDA's decision as an opportunity to demonstrate the relative heart risks of older pain drugs, such as Mobic, diclofenac, and ibuprofen.

Statistics:

  • $1 billion: annual sales of cox-2 inhibitors in 1999.
  • September: Merck withdrew Vioxx, a cox-2 blockbuster, due to concerns over its safety.
  • 1999: Cox-2 inhibitors were launched as super-aspirin painkillers.
  • 2005: FDA intervened against Pfizer's Bextra and Celebrex.

Sources:

  • Financial Times Limited 2005. All Rights Reserved.
  • Article copyrighted 2005, no specific date.